Anavex Life Sciences Announces Appointment of Ms Jiong Ma, PhD to Board of Directors

Anavex Life Sciences Announces Appointment of Ms Jiong Ma, PhD to Board of Directors Strengthening Board of Directors with Expertise in Innovative Product Launches   NEW YORK – May 26, 2021 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and…

Anavex Life Sciences to Announce Fiscal 2021 Second Quarter Financial Results and Business Outlook on Thursday, May 13, 2021

Anavex Life Sciences to Announce Fiscal 2021 Second Quarter Financial Results and Business Outlook on Thursday, May 13, 2021 Conference Call and Webcast To be Held Thursday, May 13, 2021 4:30 pm Eastern Time   NEW YORK – May 6, 2021 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical…

Anavex Life Sciences Reports the Results of Review by the Independent Data Safety Monitoring Board for its Phase 2/3 Trials of ANAVEX®2-73 in Patients with Rett Syndrome

Anavex Life Sciences Reports the Results of Review by the Independent Data Safety Monitoring Board for its Phase 2/3 Trials of ANAVEX®2-73 in Patients with Rett Syndrome NEW YORK – April 12, 2021 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of…

Anavex Life Sciences to Present at the H.C. Wainwright Global Life Sciences Conference

Anavex Life Sciences to Present at the H.C. Wainwright Global Life Sciences Conference  NEW YORK – March 4, 2021 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central…

Anavex Life Sciences Announces Participation at Upcoming Worldwide National Institutes of Health (NIH) Panel at Rare Disease Day®

Anavex Life Sciences Announces Participation at Upcoming Worldwide National Institutes of Health (NIH) Panel at Rare Disease Day® Rare Disease Day® at NIH will be held virtually on Monday, March 1, 2021, from 10:30 a.m. to 5:30 p.m. EST   NEW YORK – February 22, 2021 – Anavex Life Sciences Corp. (“Anavex” or the “Company”)…

 Anavex Life Sciences to Present at the 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021

 Anavex Life Sciences to Present at the 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021  NEW YORK – February 18, 2021 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease,…

Anavex Life Sciences to Announce Fiscal 2020 Year End Financial Results December 28th, 2020

Anavex Life Sciences to Announce Fiscal 2020 Year End Financial Results December 28th, 2020 Conference Call and Webcast To be Held Monday, December 28th, 2020 4:30 pm Eastern Time   NEW YORK – December 22, 2020 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the…

Anavex Life Sciences Announces Notice of Allowance for U.S. Patent Application with Expanding Claims Covering ANAVEX®2-73 (blarcamesine) for the Treatment of Rett Syndrome and other Neurodevelopmental Disorders

Anavex Life Sciences Announces Notice of Allowance for U.S. Patent Application with Expanding Claims Covering ANAVEX®2-73 (blarcamesine) for the Treatment of Rett Syndrome and other Neurodevelopmental Disorders   Issuance of Its Newest U.S. Patent Will Strengthen Anavex’s Compounds Intellectual Property Portfolio   NEW YORK – November 30, 2020 – Anavex Life Sciences Corp. (“Anavex” or…

Anavex Life Sciences to Present at the Evercore ISI 3rd Annual HealthCONx Conference

Anavex Life Sciences to Present at the Evercore ISI 3rd Annual HealthCONx Conference   NEW YORK – November 25, 2020 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other…

 Anavex Life Sciences Reports Fiscal 2020 Third Quarter Financial Results And Provides Business Updates

 Anavex Life Sciences Reports Fiscal 2020 Third Quarter Financial Results And Provides Business Updates Conference Call and Webcast Today at 11:00 a.m. ET   NEW YORK – August 6, 2020 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders…